.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,789,163

« Back to Dashboard

Details for Patent: 5,789,163

Title: Enzyme linked oligonucleotide assays (ELONAS)
Abstract:This invention discloses novel immunoassay termed an ELONA, employing nucleic acid ligands as capture molecules and/or detector molecules.
Inventor(s): Drolet; Dan W. (Boulder, CO), Jayasena; Sumedha D. (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Jun 07, 1995
Application Number:08/487,425
Claims:1. A method for detecting the presence of a target compound in a substance which may contain said target compound comprising:

a) identifying a nucleic acid ligand from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of said target compound, by the method comprising:

i) contacting the candidate mixture with said target compound, wherein nucleic acids having an increased affinity to said target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

ii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

iii) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids; and

iv) identifying said nucleic acid ligand;

b) exposing a substance which may contain said target compound to a capture molecule which binds to said target compound;

c) removing the remainder of said substance from said capture molecule:target compound complex;

d) adding to said capture molecule:target compound complex a detector molecule which binds to said target compound; and

e) detecting said capture molecule:target compound:detector molecule complex; wherein said capture molecule, said detector molecule or both comprise a nucleic acid ligand to said target compound identified by the method of step (a).

2. The method of claim 1 wherein said detector molecule comprises an enzyme.

3. The method of claim 2 wherein said detection is accomplished by the addition of a substrate which said enzyme can hydrolyze thereby producing a measurable color.

4. The method of claim 2 wherein said enzyme is selected from the group consisting of horseradish peroxidase, alkaline phosphatase, and .beta.-galactosidase.

5. The method of claim 1 wherein said capture molecule is bound to a solid carrier.

6. The method of claim 1 wherein said target compound is a protein.

7. The method of claim 6 wherein said protein is selected from the group consisting of Vascular Endothelial Growth Factor (VEGF), Human Chorionic Gonadotropin (hCG) and Human Thyroid Stimulating Hormone (hTSH).

8. The method of claim 1 wherein said substance is a biological fluid.

9. The method of claim 8 wherein said biological fluid is selected from the group consisting of blood, plasma, serum, sputum, urine, semen, cerebrospinal fluid, bronchial aspirate, and macerated tissue.

10. The method of claim 1 wherein said detection is achieved by PCR amplification of said nucleic acid ligand.

11. The method of claim 10 wherein the primers used for PCR amplification further comprise reporter groups.

12. The method of claim 11 wherein said reporter groups are biotin or an enzyme.

13. A method for detecting the presence of a protein in a substance which may contain said protein, wherein said protein does not have the known physiological biological function of binding a nucleic acid, comprising:

a) identifying a nucleic acid ligand from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of said protein, by the method comprising:

i) contacting the candidate mixture with said protein, wherein nucleic acids having an increased affinity to said protein relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

ii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

iii) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids; and

iv) identifying said nucleic acid ligand;

b) exposing a substance which may contain said protein to a capture molecule which binds to said protein;

c) removing the remainder of said substance from said capture molecule:protein complex;

d) adding to said capture molecule:protein complex a detector molecule which binds to said protein; and

e) detecting said capture molecule:protein:detector molecule complex, wherein said capture molecule, said detector molecule or both comprise a nucleic acid ligand to said protein.

14. The method of claim 13 wherein said detector molecule comprises an enzyme.

15. The method of claim 13 wherein said capture molecule is bound to a solid carrier.

16. The method of claim 13 wherein said protein is selected from the group consisting of Vascular Endothelial Growth Factor (VEGF), Human Chorionic Gonadotropin (hCG) and Human Thyroid Stimulating Hormone (hTSH).

17. The method of claim 13 wherein said substance is a biological fluid.

18. The method of claim 17 wherein said biological fluid is selected from the group consisting of blood, plasma, serum, sputum, urine, semen, cerebrospinal fluid, bronchial aspirate and macerated tissue.

19. The method of claim 14 wherein said detection is accomplished by the addition of a substrate which said enzyme can hydrolyze, thereby producing a measurable color.

20. The method of claim 14 wherein said enzyme is selected from the group consisting of horseradish peroxidase, alkaline phosphatase and .beta.-galactosidase.

21. The method of claim 13 wherein said detection is achieved by PCR amplification of said nucleic acid ligand.

22. The method of claim 21 wherein the primers used for PCR amplification further comprise reporter groups.

23. The method of claim 22 wherein said reporter groups are biotin or an enzyme.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc